Morning infusions may boost immunotherapy survival benefit, major analysis finds

The time of day at which patients with advanced cancer receive immune checkpoint inhibitors may be far more consequential than clinicians have traditionally assumed. A new systematic review and meta-analysis published in the British Journal of Cancer has pooled data from 43 retrospective cohort studies covering 11,941 patients with advanced solid tumors, and its central finding is striking: infusions delivered earlier in the day were associated with substantially longer overall survival and progression-free survival than infusions given later. The work, led by Zhao Jin and colleagues at Peking University Cancer Hospital & Institute, represents the most comprehensive quantitative synthesis to date of what has been a scattered but increasingly provocative body of chronotherapy research in oncology.

Immune checkpoint inhibitors, including antibodies that block PD-1, PD-L1 and CTLA-4, have transformed the treatment landscape for melanoma, lung cancer, renal cell carcinoma, head and neck cancer and many other malignancies. These drugs work by releasing the molecular brakes that tumors place on T cells, allowing the patient’s own immune system to recognize and attack cancer cells. Yet response rates remain highly variable, and a great deal of research has focused on biomarkers that predict who will benefit. The idea that something as simple as the clock time of an infusion could tip the balance is a radical departure from that framework, but it rests on a solid biological foundation: the immune system itself is governed by circadian rhythms.

The new analysis systematically searched Embase, PubMed and Scopus for studies published before April 1, 2026, that compared efficacy outcomes between early and late time-of-day administration of checkpoint inhibitors. The researchers pooled hazard and risk ratios using a random-effects model, the standard approach for combining results across heterogeneous studies. The primary endpoints were overall survival and progression-free survival, while secondary outcomes included objective response rates and immune-related adverse events. This methodological framework, aligned with the PRISMA 2020 reporting guidelines, allowed the team to quantify the timing effect with a precision that no single retrospective study could achieve.

The headline results are remarkable in their magnitude. Early time-of-day infusion was associated with an overall survival hazard ratio of 0.60, with a 95 percent confidence interval of 0.53 to 0.67. In practical terms, patients whose immunotherapy was delivered earlier in the day had roughly a 40 percent lower risk of death during the observation periods studied compared with those infused later. Progression-free survival showed a similar pattern, with a hazard ratio of 0.65, and the objective response rate was 37 percent higher in the early-infusion group, with a relative risk of 1.37. For a field in which new drugs routinely celebrate hazard ratios in the range of 0.70 to 0.80, an apparent effect of this size from altering an appointment time is extraordinary, and it is precisely why the study has captured so much attention.

Crucially, the safety picture showed no difference. Neither any-grade immune-related adverse events, with a relative risk of 0.98, nor grade 3 or higher immune-related adverse events, with a relative risk of 0.95, differed between early and late infusions. That is an important signal, because it suggests the timing effect operates on efficacy rather than toxicity, which is consistent with mechanistic studies showing that circadian biology shapes the strength and character of anti-tumor immune responses rather than simply modulating drug clearance or side effects.

The mechanistic rationale for these findings comes from more than a decade of immunology research. Circadian clocks, driven by core clock genes expressed in virtually every immune cell type, regulate the trafficking of lymphocytes through lymph nodes and tissues, the daily fluctuations of cytokine production, and the rhythmic expression of immune checkpoints themselves. Animal studies have shown that PD-1 expression on tumor-associated macrophages varies across the day, and a landmark 2023 Nature study demonstrated that dendritic cells direct circadian anti-tumor immune responses, meaning the very cells that present tumor antigens to T cells are more potent at certain times of day. Work published in Nature Immunology in 2024 further showed that circadian control of tumor immunosuppression directly affects the efficacy of checkpoint blockade in mouse models. Earlier chronotherapy research in chemotherapy, championed by investigators such as Francis Lévi, had already established that drug timing can dramatically alter both efficacy and toxicity, but extending that principle to immunotherapy, whose effects depend on host immunity rather than direct cytotoxicity, is a conceptual leap.

However, the authors are careful, and the analysis itself demands caution. Significant publication bias was detected using Egger’s test, with a p-value below 0.001, indicating that smaller studies with positive results may have been preferentially published. When the team applied trim-and-fill adjustment, a statistical method that estimates and corrects for missing negative studies, the overall survival association remained significant but was attenuated, with an adjusted hazard ratio of 0.79. The progression-free survival result was weakened further, its adjusted hazard ratio of 0.89 carrying a confidence interval that reached the null boundary after rounding. In other words, the true effect, while likely real, is probably considerably smaller than the unadjusted numbers suggest, and for progression-free survival the evidence does not yet clear the statistical bar.

There are also inherent limitations in the evidence base itself. Every one of the 43 included studies was retrospective, meaning patients were not randomly assigned to infusion times, and confounding is a persistent threat. Sicker patients may be scheduled later in the day for practical reasons, and clinic scheduling patterns may correlate with treatment line, tumor type, institution or era of care. The studies also varied in how they defined the cutoff between early and late administration, which the authors illustrated in their methodological distribution analysis, and meta-regression of the association between the time-of-day cutoff and survival outcomes was used to explore this heterogeneity. Observational data, however carefully adjusted, cannot exclude the possibility that unmeasured factors drive part or all of the apparent effect.

For this reason, the authors conclude that the current evidence is insufficient to warrant an immediate change in clinical practice, and they are explicit that no guideline body, whether ASCO, ESMO or the NCCN, has endorsed timing-based scheduling. Yet the findings provide what they describe as a compelling rationale for prospective trials. Notably, a randomized phase 3 trial of time-of-day immunochemotherapy in non-small cell lung cancer, published in Nature Medicine in 2026, has already begun to test the hypothesis directly, and additional prospective efforts such as the ETOP-Roche i-TIMES investigation into immunotherapy timing and lung cancer survival are underway. These studies, unlike the retrospective cohorts synthesized here, will randomize patients to infusion windows and thereby eliminate most confounding.

The broader implications are tantalizing. If even a fraction of the observed effect survives prospective validation, the consequences would be enormous: immunotherapy is delivered to hundreds of thousands of patients worldwide, and optimizing infusion timing would be among the cheapest, most scalable interventions in modern oncology, requiring nothing more than a scheduling change. It would also open the door to personalizing chronotherapy by internal circadian phase, using blood-based molecular clocks or wearable sleep and activity biomarkers to determine each patient’s optimal window rather than relying on clock time alone. Considerations of shift work, melatonin profiles, glucocorticoid rhythms and even the circadian gut microbiome could all come into play. For now, patients and clinicians should resist the urge to reshuffle appointments based on retrospective data, but they should also pay close attention as the randomized trials mature. The clock, this analysis suggests, may be a genuinely untapped variable in cancer immunotherapy, and the field is only beginning to learn how to read it.

Subject of Research: Effect of time-of-day immune checkpoint inhibitor infusion timing on survival outcomes in advanced solid tumors

Article Title: Unlocking the clock: a systematic review and meta-analysis on optimizing immune checkpoint inhibitor timing for advanced solid tumors

Article References: Unlocking the clock: a systematic review and meta-analysis on optimizing immune checkpoint inhibitor timing for advanced solid tumors. (n.d.). https://doi.org/10.1038/s41416-026-03598-5

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03598-5

Keywords: immunotherapy, immune checkpoint inhibitors, circadian rhythm, chronotherapy, meta-analysis, solid tumors, overall survival, progression-free survival, PD-1, British Journal of Cancer, cancer research, publication bias